It Didn’t Invent the Drug. It Didn’t Run the Trials.
It In-Licensed the Rest-of-World Rights.

In 2026, a company called Braveheart Bio filed its S-1, the registration statement a company must file with U.S. securities regulators before going public. What it wants to do is treat a disease in which the heart muscle grows too thick, using a pill. The drug at the center of that plan, however, is not one the company made. It is a drug discovered by a Chinese pharmaceutical company, obtained under a license.

Braveheart has never run the human trials of that drug, either. The chemistry and the testing were both done by the Chinese company, Hengrui. What Braveheart licensed was the drug, the data from those trials, and the exclusive right to develop and sell it everywhere in the world outside Greater China, meaning mainland China, Hong Kong, Macau, and Taiwan.

The money runs like this. Upfront consideration of $58.2 million has already gone to Hengrui: $32.5 million in cash, plus 32.5 million shares of non-voting preferred stock with an estimated fair value of $25.7 million. Beyond that, up to $23.0 million is payable as technology-transfer and development milestones are met, part of which has already been achieved and paid, and up to $1.0 billion upon achievement of specified commercial milestones. On top of those, Hengrui receives 5% to 10% of Braveheart’s total annual net sales of the drug, for a defined term.

The company sells nothing yet, and its accumulated deficit stands at about $80.3 million. Cash was about $80.6 million at the end of March. This is a U.S. startup that in-licensed a Chinese-born drug, and is about to take it into the pivotal trials it has never once run itself.

Ten questions. We lay out only what the S-1 says.

Question 1

What is this company, really?

In one line: a company carrying a Chinese heart drug to the rest of the world.

Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle thickens abnormally. When the walls grow thick, the heart may have trouble relaxing and filling, and in the obstructive form, the flow of blood out of the heart can be restricted as well. People get short of breath and feel their heart pound; in severe cases it can lead to heart failure or sudden cardiac death. It affects more than 700,000 people in the United States alone, the company writes.

The company’s drug, BHB-1893, is an oral drug meant to ease the thickened heart’s tendency to squeeze too hard. It belongs to a class that damps the contraction of the heart muscle, and it is being developed both for the form in which the outflow of blood is obstructed and for the form in which it is not.

The heart of the story is where this drug came from. BHB-1893 was discovered and developed by the Chinese pharmaceutical company Hengrui, which calls it HRS-1893 in China. In September 2025, Braveheart obtained it under an exclusive license.

At the front of the S-1, the company states what it is aiming for.

“

Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.

BRAVEHEART BIO S-1 (2026) — PROSPECTUS SUMMARY

One thing should be made clear before going further. BHB-1893 is an investigational candidate, not an approved medicine: the filing states plainly that the company does not have any products approved for sale. This article does not recommend its efficacy or safety. Every figure that follows comes from trials run by Hengrui or from what is written in the filing.

A clinical-stage company taking an oral heart drug born in China out to the world.

Question 2

What does it compete on?

The case for this drug rests on three claims. Take them in turn.

The strengths the company puts forward fall into three groups: the weakness of the drugs that got there first, ease of use, and the quality of the effect. Start with the two rival drugs already on the market.

The rival drugs carry an “LVEF cost”

Two drugs of the same class were approved before this one: mavacamten (sold as Camzyos) and aficamten (sold as MYQORZO). Both lower the obstruction at the heart’s outflow. But as the dose goes up, the company says, the heart’s ability to push blood out falls along with it.

The company calls this the “LVEF cost,” the price paid in lost pumping power. Its point is that pumping power can slide toward an unsafe level before the obstruction has been brought all the way down, leaving some people still symptomatic. In the pivotal trials of those earlier drugs, the share of patients whose obstruction fell to the target was 49% on aficamten and 57% on mavacamten. The two figures come from two different trials, measured at different points and against differently defined targets, so they are not a like-for-like comparison.

On top of that, because of the worry about losing pumping power, the dose must be raised in a careful, multi-step process, and the heart must be checked frequently by ultrasound. That burden has held back real-world uptake, the company argues.